Cite
HARVARD Citation
Furstenau, D. et al. (2022). Alemtuzumab clearance, lymphocyte count, and T‐cell chimerism after hematopoietic stem cell transplant in sickle cell disease. Pharmacotherapy. 42 (1), pp. 14-22. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Furstenau, D. et al. (2022). Alemtuzumab clearance, lymphocyte count, and T‐cell chimerism after hematopoietic stem cell transplant in sickle cell disease. Pharmacotherapy. 42 (1), pp. 14-22. [Online].